Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Ader

Showing results (141-150 of 169) with videos related to

Pageof 17
Sort By:
Scientific Reports|July 2, 2021
Multi-country evaluation of RISK6, a 6-gene blood transcriptomic signature, for tuberculosis diagnosis and treatment monitoringRim Bayaa, Mame Diarra Bousso Ndiaye, Carole Chedid, et al.
Pharmacology Research & Perspectives|June 3, 2023
Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trialNoémie Mercier, Drifa Belhadi, Aline DeChanet, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2020
Cluster of Coronavirus Disease 2019 (COVID-19) in the French Alps, February 2020Kostas Danis, Olivier Epaulard, Thomas Bénet, et al.
Iscience|January 7, 2026
Viral clearance and escape during therapy of COVID-19 outpatients: A prospective cohort studyGuillaume Martin-Blondel, Paul Burgat, Valentin Leducq, et al.
The Journal of Infection|December 16, 2024
Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant Gram-negative bacteria: CEFI-IDSarah Soueges, Emmanuel Faure, Perrine Parize, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 29, 2024
Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy TrialVida Terzić, Joe Miantezila Basilua, Nicolas Billard, et al.
Frontiers in Immunology|February 19, 2021
Relevance of QuantiFERON-TB Gold Plus and Heparin-Binding Hemagglutinin Interferon-γ Release Assays for Monitoring of Pulmonary Tuberculosis Clearance: A Multicentered StudyCarole Chedid, Eka Kokhreidze, Nestani Tukvadze, et al.
British Journal of Clinical Pharmacology|January 21, 2023
Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortiaVida Terzić, Léa Levoyer, Mélanie Figarella, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 11, 2021
Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group, Alpha Diallo, Marius Trøseid, et al.
Chest|July 7, 2023
Improving Diagnosis of Pulmonary Mucormycosis: Leads From a Contemporary National Study of 114 CasesAnne Coste, Anne Conrad, Raphaël Porcher, et al.
Pageof 17

Showing results (141-150 of 169) with videos related to

Sort By:
Pageof 17
Scientific Reports|July 2, 2021
Multi-country evaluation of RISK6, a 6-gene blood transcriptomic signature, for tuberculosis diagnosis and treatment monitoringRim Bayaa, Mame Diarra Bousso Ndiaye, Carole Chedid, et al.
Pharmacology Research & Perspectives|June 3, 2023
Management of pharmacovigilance during the COVID-19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trialNoémie Mercier, Drifa Belhadi, Aline DeChanet, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 12, 2020
Cluster of Coronavirus Disease 2019 (COVID-19) in the French Alps, February 2020Kostas Danis, Olivier Epaulard, Thomas Bénet, et al.
Iscience|January 7, 2026
Viral clearance and escape during therapy of COVID-19 outpatients: A prospective cohort studyGuillaume Martin-Blondel, Paul Burgat, Valentin Leducq, et al.
The Journal of Infection|December 16, 2024
Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant Gram-negative bacteria: CEFI-IDSarah Soueges, Emmanuel Faure, Perrine Parize, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 29, 2024
Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy TrialVida Terzić, Joe Miantezila Basilua, Nicolas Billard, et al.
Frontiers in Immunology|February 19, 2021
Relevance of QuantiFERON-TB Gold Plus and Heparin-Binding Hemagglutinin Interferon-γ Release Assays for Monitoring of Pulmonary Tuberculosis Clearance: A Multicentered StudyCarole Chedid, Eka Kokhreidze, Nestani Tukvadze, et al.
British Journal of Clinical Pharmacology|January 21, 2023
Implementation of a centralized pharmacovigilance system in academic pan-European clinical trials: Experience from EU-Response and conect4children consortiaVida Terzić, Léa Levoyer, Mélanie Figarella, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 11, 2021
Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group, Alpha Diallo, Marius Trøseid, et al.
Chest|July 7, 2023
Improving Diagnosis of Pulmonary Mucormycosis: Leads From a Contemporary National Study of 114 CasesAnne Coste, Anne Conrad, Raphaël Porcher, et al.
Pageof 17